Theravance Biopharma (TBPH) Share-based Compensation (2013 - 2026)
Theravance Biopharma (TBPH) reported Share-based Compensation of $4.5 million for Q1 2026, down 7.65% year-over-year from $4.9 million in Q1 2025, and up 0.54% quarter-over-quarter from $4.5 million in Q4 2025.
Theravance Biopharma (TBPH) Share-based Compensation (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Share-based Compensation data on file, last reported at $4.5 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $4.5 million, down 7.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.1 million (down 13.97% YoY), and the FY2025 annual result was $18.5 million, down 13.64% from the prior year.
- Share-based Compensation grew to $4.5 million in Q1 2026 per TBPH's latest filing, from $4.5 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $14.5 million in Q1 2022 and troughed at $4.5 million in Q4 2025.
- A 5-year average of $6.4 million and a median of $5.8 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation plunged 58.92% in 2022, then advanced 0.03% in 2024.
- A 5-year view of Share-based Compensation shows it stood at $7.0 million in 2022, then slipped by 16.2% to $5.8 million in 2023, then climbed by 0.03% to $5.8 million in 2024, then decreased by 23.1% to $4.5 million in 2025, then increased by 0.54% to $4.5 million in 2026.
- Business Quant data shows TBPH's Share-based Compensation at $4.5 million in Q1 2026, $4.5 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | 4.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.50 Mn |
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 4.48 Mn |
| Dec 31, 2025 | 4.48 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 4.88 Mn |
| Mar 31, 2025 | 4.88 Mn |
| Dec 31, 2024 | 5.83 Mn |
| Dec 31, 2024 | 5.83 Mn |
| Sep 30, 2024 | 4.96 Mn |
| Sep 30, 2024 | 4.96 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 5.82 Mn |
| Dec 31, 2023 | 5.82 Mn |